VivoSeq
Ophthalmology

Angle-Closure Glaucoma

5

Pipeline Programs↗

0

Active Trials↗

4

Companies Involved↗

Angle-Closure Glaucoma is an early-stage landscape with 5 programs across 4 companies. The most active players are Quark Pharmaceuticals, AbbVie, Advanz Pharma. 2 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

67/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Q

Quark Pharmaceuticals

1 program

Phase 2AbbVie logo

AbbVie

2 programs

Phase 3A

Advanz Pharma

1 program

ApprovedTeva logo

Teva

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

5

clinical trials

Unknown status2 · 40%
Completed2 · 40%
Terminated1 · 20%

Clinical Trials

Trial Activity

Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)
Terminated·AAlcon Research·Phase 4·NCT00758342·37 enrolled
A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Chronic Angle-closure Glaucoma
Unknown status·NNew York Glaucoma Research Institute·Phase 2·NCT02152774·10 enrolled
Comparison of Bimatoprost and Latanoprost in Patients With Chronic Angle-Closure Glaucoma: A Randomized Cross-Over Study
Unknown status·SSingapore National Eye Centre·N/A·NCT00567788·60 enrolled
A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma
Completed·AAlcon Research·Phase 3·NCT00051181
Phase IIA Double-Masked Randomized Sham-Controlled Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Subjects With Acute Primary Angle-Closure Glaucoma (APACG)
Completed·QQuark Pharmaceuticals·Phase 2·NCT01965106·46 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)